Mizuho Reiterates Neutral Rating on Athira Pharma (ATHA) Dec 19, 2025 04:06AM
Athira Pharma, Inc. (ATHA) Misses Q3 EPS by 155c Nov 6, 2025 06:23PM
Athira Pharma (ATHA) PT Raised to $4 at Mizuho Sep 19, 2025 05:42AM
Citizens JMP Reiterates Market Perform Rating on Athira Pharma (ATHA) May 12, 2025 04:36AM
Athira Pharma, Inc. (ATHA) Misses Q1 EPS by 5c May 9, 2025 05:07PM


Nov 8, 2024 06:28AM Athira Pharma, Inc. (ATHA) Misses Q3 EPS by 5c
Oct 21, 2024 06:31AM Athira Pharma Inc. (ATHA) Files $300M Mixed Shelf
Sep 19, 2024 04:17AM Mizuho Downgrades Athira Pharma (ATHA) to Neutral
Sep 17, 2024 09:06AM Athira Pharma (ATHA) to cut 70% staff
Sep 4, 2024 06:41AM Mizuho Reiterates Outperform Rating on Athira Pharma (ATHA)
Sep 4, 2024 02:09AM JMP Securities Downgrades Athira Pharma (ATHA) to Market Perform
Sep 4, 2024 02:00AM BTIG Downgrades Athira Pharma (ATHA) to Neutral
Sep 3, 2024 04:01PM Athira Pharma Inc. (ATHA) Reports Topline Results from Phase 2/3 LIFT-AD Trial of Fosgonimeton
Sep 3, 2024 04:00PM Athira Pharma Inc. (ATHA) Halted, News Pending
Aug 1, 2024 05:45PM Athira Pharma, Inc. (ATHA) Tops Q2 EPS by 4c
Jul 31, 2024 08:05AM Athira Pharma (ATHA) Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology